Cantargia presenterar tidiga resultat frÄn en prövarinitierad fas Ib/IIa-studie med nadunolimab vid högrisk myelodysplastiskt syndrom och akut myeloisk leukemi. https://t.co/RmBK0cTH5b
Cantargia presenterar prekliniska resultat som visar tumörhÀmmande effekter av nadunolimab i metastatisk kolorektalcancer
$CANTA #IL1RAP
https://t.co/QxSrWRrGT2
Our base case of SEK8.5 includes a risk-adjusted late-stage deal with nadunolimab in 2030 on the back of a
positive pancreatic cancer phase III study, with a total deal value of USD3bn of which USD1bn upfront and 25%
royalties
$CANTA #CANTARGIA
https://t.co/0KFeSwJCui
Myeloid-stromal IL1RAP as a therapeutic vulnerability in pancreatic cancer
âThese findings support an upcoming neo-adjuvant trial combining CAN04 with chemoimmunotherapy in patients with operable PDACâ
CANTARGIA #IL1RAP $CANTA
https://t.co/f1gYxpvnli
âDen vetenskapliga motiveringen för att anvĂ€nda en ny IL1RAP-riktad metod med nadunolimab Ă€r övertygande, och vi ser fram emot att generera data som kan ge framtida immunterapistrategierâ
$CANTA #CANTARGIA#IL1RAP
https://t.co/l3iPJnXAgd
Ytterligare en IL1RAP antikropp inom autoimmuna och inflammatoriska sjukdomar, kan bli intressant nÀr det blir kommersiella produkter mot IL1RAP nÀr Cantargia sitter pÄ bÄde produktpatent men Àven mÄltavlan IL1RAP för antikroppar.
$CANTA
https://t.co/Jabie757vJ
Intressant utveckling inom IL1RAP
Sanofi och Almirall Ă€r pĂ„ vĂ€g in i fas 2 med sina IL1RAP-antikroppar mot HS â samma indikation som Otsuka utvecklar CAN10 för.
BÄda företagen har överklagat Cantargia's IL1RAP-patent flera gÄnger i EU, US och JP⊠men förlorat varje gÄng.
CANTARGIA at AACR PDAC 2025
These data collectively suggest that IL1RAP is highly relevant in PDAC and can be meaningfully targeted by Nadunolimab
These findings support an upcoming neoadjuvant trial combining Nadunolimab with chemoimmunotherapy in patients with operable PDAC
Read the just-published article mentioned in this story: Elevated clonal hematopoiesis in 9/11 first responders has distinct age-related patterns and relies on IL1RAP for clonal expansion https://t.co/ceyiI1amKO
@Longterms1@Gothiaace Ge upp Gothia., han kommenterar inte ens det senaste frÄn AACR. Cherrypicker som hypar sina egna innehav som svansen köper upp Ät honom.
Congratulations on the presentation! Exploring IL1RAP inhibition could significantly advance the fight against #PancreaticCancer, which has shown resistance to many conventional therapies. Can you share what specific chemoimmunotherapy combinations you're investigating, or how far along you are in the clinical trial phases? #Medicine
For more in-depth reviews on similar biomedical strategies, check out https://t.co/4Y9Imt8uIJ, a platform that aids in understanding the complex landscape of biomedical research by generating comprehensive reviews.
Elevated clonal hematopoiesis in 9/11 first responders has distinct age-related patterns and relies on IL1RAP for clonal expansion https://t.co/MTeYS1AxjT @Amitvermamds@SteidlUli